Drugs / 611
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06173284 | Jan 2024 → Sep 2025 | atopic eczema | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 611 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06173284 ↗ |
| Action | Inhibit | “Anti-interleukin-4 Receptor Alpha” NCT06173284 ↗ |
| Modality | Monoclonal antibody | “IgG4 Monoclonal Antibody” NCT06173284 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT06173284 ↗ |